Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Weekly Paclitaxel/Nab-paclitaxel + Keytruda + Mirabegron in Recurrent Ovarian Cancer
ChiCTR2500113415Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel and mirabegron in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Objective Response Rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500113415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113415.